Information about Vilazodone
Vilazodone is a selective serotonin reuptake inhibitor (SSRI) and partial serotonin receptor agonist which is used in the therapy of major depressive disorders.
Liver safety of Vilazodone
In premarketing clinical trials, vilazodone therapy was not associated with an increased rate of elevations in serum aminotransferase levels, and it has yet to be linked to instances of clinically apparent acute liver injury.
Mechanism of action of Vilazodone
Vilazodone (vil az' oh done) is an SSRI that acts by blocking the reuptake of serotonin in CNS synaptic clefts, thus increasing serotonin levels in the brain which is associated with its psychiatric effects. Vilazodone is also a partial serotonin (5-HT1A) receptor agonist, which may add to its antidepressant effects.
FDA approval information for Vilazodone
Vilazodone was approved for use in the United States in 2011 for use in treatment of major depressive disorder. There is limited clinical experience with its use.
Brand name for Vilazodone
Vilazodone is available as tablets of 10, 20 and 40 mg under the brand name Viibryd.
Dosage and administration for Vilazodone
The recommended initial dose of vilazodone in adults is 10 mg daily, which can then be increased to the typical maintenance dose of 40 mg once daily.
Side effects of Vilazodone
Common, non-serious side effects include diarrhea, nausea, fatigue, drowsiness, headache, insomnia, weight gain and sexual dysfunction. Overdose is associated with acute serotonin syndrome. Rare, but potentially severe adverse effects include suicidal thinking and behavior, activation of symptoms of mania, sexual dysfunction, hyponatremia and hypersensitivity reactions.
The following are antidepressant subclasses and drugs